Author: Steve Kennedy

Antibody Drug Conjugates: The Patent Landscape for a New Class of Cancer Treatment

Over the last decade, antibody-drug conjugates (ADCs) have emerged as a highly promising new class of biopharmaceuticals. By taking advantage of the specificity of monoclonal antibodies and the potency of small-molecule chemotherapy drugs, ADCs have proven to provide a highly effective combination – particularly in the oncology space,. The recent […]